We narrowed to 261 results for: Son
-
Viral Prep#187180-AAV9PurposeReady-to-use AAV9 particles produced from pAAV_hSyn1_nLightR (#187180). In addition to the viral particles, you will also receive purified pAAV_hSyn1_nLightR plasmid DNA. Syn-driven expression of red norepinephrine sensor nLightR. These AAV preparations are suitable purity for injection into animals.DepositorPromoterhuman Synapsin-1TagsNoneAvailable sinceJune 21, 2024AvailabilityAcademic Institutions and Nonprofits only
-
pAAV-CaMKIIa-C1V1 (t/t)-TS-EYFP (AAV9)
Viral Prep#35499-AAV9PurposeReady-to-use AAV9 particles produced from pAAV-CaMKIIa-C1V1 (t/t)-TS-EYFP (#35499). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-C1V1 (t/t)-TS-EYFP plasmid DNA. CaMKIIa-driven, C1V1 (t/t) fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCaMKIITagsEYFPAvailable sinceApril 6, 2018AvailabilityAcademic Institutions and Nonprofits only -
pAAV.GFAP.SF-iGluSnFR.A184S (AAV1)
Viral Prep#106192-AAV1PurposeReady-to-use AAV1 particles produced from pAAV.GFAP.SF-iGluSnFR.A184S (#106192). In addition to the viral particles, you will also receive purified pAAV.GFAP.SF-iGluSnFR.A184S plasmid DNA. GFAP-driven expression of SF-iGluSnFR.A184S. These AAV preparations are suitable purity for injection into animals.DepositorPromoterGFAPTagsNoneAvailable sinceSept. 11, 2020AvailabilityAcademic Institutions and Nonprofits only -
pAAV-EF1a-vCre (AAV8)
Viral Prep#55638-AAV8PurposeReady-to-use AAV8 particles produced from pAAV-EF1a-vCre (#55638). In addition to the viral particles, you will also receive purified pAAV-EF1a-vCre plasmid DNA. EF1a-driven expression of VCre. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsNoneAvailable sinceNov. 12, 2020AvailabilityAcademic Institutions and Nonprofits only -
pAAV-Ef1a-DIO-ChRmine-mScarlet-WPRE (AAV5)
Viral Prep#130998-AAV5PurposeReady-to-use AAV5 particles produced from pAAV-Ef1a-DIO-ChRmine-mScarlet-WPRE (#130998). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-ChRmine-mScarlet-WPRE plasmid DNA. Ef1a-driven, Cre-dependent expression of ChRmine-mScarlet. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsmScarletAvailable sinceMarch 18, 2024AvailabilityAcademic Institutions and Nonprofits only -
pAAV-hSyn-ChRmine-mScarlet-Kv2.1-WPRE (AAV8)
Viral Prep#130995-AAV8PurposeReady-to-use AAV8 particles produced from pAAV-hSyn-ChRmine-mScarlet-Kv2.1-WPRE (#130995). In addition to the viral particles, you will also receive purified pAAV-hSyn-ChRmine-mScarlet-Kv2.1-WPRE plasmid DNA. hSyn-driven, soma-targeted ChRmine-mScarlet expression. These AAV preparations are suitable purity for injection into animals.DepositorPromoterSynTagsmScarletAvailable sinceJan. 6, 2022AvailabilityAcademic Institutions and Nonprofits only -
pAAV-CaMKIIa-ChRmine-mScarlet-Kv2.1-WPRE (AAV8)
Viral Prep#130991-AAV8PurposeReady-to-use AAV8 particles produced from pAAV-CaMKIIa-ChRmine-mScarlet-Kv2.1-WPRE (#130991). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-ChRmine-mScarlet-Kv2.1-WPRE plasmid DNA. CamKIIa-driven, soma-targeted ChRmine-mScarlet expression. These AAV preparations are suitable purity for injection into animals.DepositorPromoterCaMKIITagsmScarletAvailable sinceJan. 6, 2022AvailabilityAcademic Institutions and Nonprofits only -
pAAV-Ef1a-DIO-ChRmine-mScarlet-WPRE (AAV1)
Viral Prep#130998-AAV1PurposeReady-to-use AAV1 particles produced from pAAV-Ef1a-DIO-ChRmine-mScarlet-WPRE (#130998). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-ChRmine-mScarlet-WPRE plasmid DNA. Ef1a-driven, Cre-dependent expression of ChRmine-mScarlet. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsmScarletAvailable sinceSept. 27, 2024AvailabilityAcademic Institutions and Nonprofits only -
pAAV-Ef1a-DIO eNpHR 3.0-EYFP (AAV Retrograde)
Viral Prep#26966-AAVrgPurposeReady-to-use AAV Retrograde particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsEYFP (Cre-dependent)Available sinceMarch 27, 2024AvailabilityAcademic Institutions and Nonprofits only -
pAAV.hSynapsin.SF-iGluSnFR.A184S (AAV9)
Viral Prep#106174-AAV9PurposeReady-to-use AAV9 particles produced from pAAV.hSynapsin.SF-iGluSnFR.A184S (#106174). In addition to the viral particles, you will also receive purified pAAV.hSynapsin.SF-iGluSnFR.A184S plasmid DNA. hSynapsin driven SF-iGluSnFR.A184S glutamate sensor. The A184S mutant has a higher glutamate affinity. These AAV preparations are suitable purity for injection into animals.DepositorPromoterSynTagsNoneAvailable sinceFeb. 14, 2024AvailabilityAcademic Institutions and Nonprofits only -
pAAV.hSynapsin.SF-iGluSnFR.A184S (AAV1)
Viral Prep#106174-AAV1PurposeReady-to-use AAV1 particles produced from pAAV.hSynapsin.SF-iGluSnFR.A184S (#106174). In addition to the viral particles, you will also receive purified pAAV.hSynapsin.SF-iGluSnFR.A184S plasmid DNA. hSynapsin driven SF-iGluSnFR.A184S, glutamate sensor. The A184S mutant has a higher glutamate affinity. These AAV preparations are suitable purity for injection into animals.DepositorPromoterSynTagsNoneAvailable sinceJune 20, 2018AvailabilityAcademic Institutions and Nonprofits only -
pAAV-Ef1a-fDIO EYFP (AAV1)
Viral Prep#55641-AAV1PurposeReady-to-use AAV1 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsEYFP (Flp-dependent)Available sinceAug. 28, 2020AvailabilityAcademic Institutions and Nonprofits only -
pAAV-Ef1a-fDIO EYFP (AAV9)
Viral Prep#55641-AAV9PurposeReady-to-use AAV9 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsEYFP (Flp-dependent)Available sinceFeb. 25, 2021AvailabilityAcademic Institutions and Nonprofits only -
pAAV-Ef1a-fDIO EYFP (AAV8)
Viral Prep#55641-AAV8PurposeReady-to-use AAV8 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsNoneAvailable sinceDec. 18, 2024AvailabilityAcademic Institutions and Nonprofits only -
pAAV-Ef1a-fDIO EYFP (AAV5)
Viral Prep#55641-AAV5PurposeReady-to-use AAV5 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsEYFP (Flp-dependent)Available sinceOct. 21, 2024AvailabilityAcademic Institutions and Nonprofits only -
pAAV-Ef1a-fDIO EYFP (AAV2)
Viral Prep#55641-AAV2PurposeReady-to-use AAV2 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsEYFP (Flp-dependent)Available sinceSept. 27, 2023AvailabilityAcademic Institutions and Nonprofits only -
pAAV-Ef1a-DIO C1V1 (t/t)-TS-EYFP (AAV9)
Viral Prep#35497-AAV9PurposeReady-to-use AAV9 particles produced from pAAV-Ef1a-DIO C1V1 (t/t)-TS-EYFP (#35497). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO C1V1 (t/t)-TS-EYFP plasmid DNA. EFIa-driven, Cre-dependent, C1V1 (t/t) fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsEYFP (Cre-dependent)Available sinceMarch 30, 2018AvailabilityAcademic Institutions and Nonprofits only -
pAAV-hSyn-GCaMP 6m-p2A-ChRmine-Kv2.1-WPRE (AAV8)
Viral Prep#131004-AAV8PurposeReady-to-use AAV8 particles produced from pAAV-hSyn-GCaMP 6m-p2A-ChRmine-Kv2.1-WPRE (#131004). In addition to the viral particles, you will also receive purified pAAV-hSyn-GCaMP 6m-p2A-ChRmine-Kv2.1-WPRE plasmid DNA. hSyn-driven expression of calcium sensor GCaMP6m and bicistronic ChRmine (red-shifted channelrhodopsin). These AAV preparations are suitable purity for injection into animals.DepositorPromoterSynTagsNoneAvailable sinceJune 4, 2020AvailabilityAcademic Institutions and Nonprofits only -
pAAV-EF1a-Cre (AAV Retrograde)
Viral Prep#55636-AAVrgPurposeReady-to-use AAV Retrograde particles produced from pAAV-EF1a-Cre (#55636). In addition to the viral particles, you will also receive purified pAAV-EF1a-Cre plasmid DNA. EF1a-driven expression of Cre recombinase. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.DepositorPromoterEF1aTagsNoneAvailable sinceNov. 12, 2020AvailabilityAcademic Institutions and Nonprofits only -
pAAV-Syn-Chronos-GFP (AAV5)
Viral Prep#59170-AAV5PurposeReady-to-use AAV5 particles produced from pAAV-Syn-Chronos-GFP (#59170). In addition to the viral particles, you will also receive purified pAAV-Syn-Chronos-GFP plasmid DNA. Syn-driven Chronos-GFP expression for optogenetic neural activation. These AAV preparations are suitable purity for injection into animals.DepositorPromoterSynTagsGFPAvailable sinceJuly 21, 2017AvailabilityAcademic Institutions and Nonprofits only